Tau protein: A possible prognostic factor in optic neuritis and multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 5, 2012, Pages 592-599

  Frederiksen, J ^a   Kristensen, K ^a   Bahl, J M C ^b   Christiansen, M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

14 3 3 protein; disease progression; multiple sclerosis; optic neuritis; tau protein

Indexed keywords

PROTEIN 14 3 3; TAU PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DENMARK; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REMISSION;

EID: 84860433059     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511424588     Document Type: Article

References (19)

1. Sorensen TL, Frederiksen JL, Bronnum-Hansen H, Petersen NC. Opticus neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term study. Neurology. 1999 ; 53: 473-478
2. Trapp B, Ransohoff R, Rudick R. Axonal pathology in multiple scleroses: relationship to neurologic disability. Curr Opin Neurol. 1999 ; 12: 295-302
3. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand. 2007 ; 115: 325-330
4. Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J Neural Transm. 2006 ; 113: 339-345
5. Süssmuth S, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett. 2001 ; 300: 95-98
6. Rostasy K, Withut E, Pohl D, Lange P, Ciesielcyk B, et al. Tau, phospho-tau and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol. 2005 ; 20: 822-825
7. Brettschneider J, Maier M, Arda S, Claus A, Süssmuth SD, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler. 2005 ; 11: 261-265
8. Colluci M, Roccagliata L, Capello E, Narciso E, Latronico N, Tabalton M, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler. 2004 ; 10: 477-481
9. Bartosik-Psujek H, Archelos J. Tau protein and 14-3-3 in the cerebrospinal fluid of patients with multiple sclerosis an correlate with intrathecal synthesis of IgG. J Neurol. 2004 ; 251: 414-420
10. Brettschneider J, Petzold A, Junker A, H Tumami. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndromes improve predicting conversion to definite multiple sclerosis. Mult Scler. 2006 ; 12: 143
11. Martinez-Yelamos A, Saiz A, Bas J, Hernandez J, Graus F, et al. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett. 2004 ; 363: 14-17
12. Martinez-Yelamos A, Rovira A, Sanchez-Valle R, Martinez-Yelamos S, Tintore M, et al. CSF 14-3-3 protein assay and MRI prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol. 2004 ; 251: 1278-1279
13. Martinez-Yelamos A, Saiz A, Sanchez-Valle R, Casado V, Ramon JM, et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology. 2001 ; 57: 722-724
14. Jimenez-Jimenez F, Zurdo J, Hernanz A, Medina-Acebron S, deBustos F, Barcenilla B, et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand. 2002 ; 106: 351-354
15. Guimarãres J, Cardoso MJ, Sá MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler. 2006 ; 12: 354-356
16. Hein (née Maier) K, Köhler A, Diem R, Sättler M, Demmer I, et al. Biological markers of axonal degeneration in CSF and blood of patients with first event indicative of multiple sclerosis. Neurosci Lett. 2008 ; 436: 72-74
17. De Seze J, Peoc'h K, Ferriby D, Stojkovic T, Laplanche J, Vermersch P. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J Neurol. 2002 ; 249: 626-627
18. Valis M, Talab R, Stourac P, Andrys C, Masopust J. Tau protein, phosphorylated tau protein and beta-amyloid 42 in the cerebrospinal fluid of multiple sclerosis patients. Neuroendocrinol Lett. 2008 ; 29: 971-976
19. Bartosik-Psujek H, Psujek M, Jaworski J, Stelmasiak Z. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand. 2011 ; 123: 252-256